ARMO BioSciences Garners $50,000,000 Series C Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=092cb83c-dfb7-45b9-91f6-f29399b0366a - Date
2/10/2016 - Company Name
ARMO BioSciences - Mailing Address
575 Chesapeake Drive Redwood City, CA 94063 USA - Company Description
ARMO BioSciences is a biopharmaceutical company that develops immunotherapies for the treatment of Cancer, Cardiovascular Diseases, Fibrosis and Inflammation. ARMO’s lead product AM0010, is a PEGylated form of recombinant human Interleukin-10 (PEG-rHuIL-10). - Website
http://www.armobio.com - Transaction Type
Venture Equity - Transaction Amount
$50,000,000 - Transaction Round
Series C - Proceeds Purposes
ARMO intends to use the proceeds from the financing to support the clinical development of its lead product candidate, AM0010 for the treatment of advanced solid tumors, and its pipeline of immunotherapies, including cytokines and an anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibody checkpoint inhibitor. - M&A Terms
- Venture Investor
Kleiner Perkins Caufield & Byers - Venture Investor
OrbiMed - Venture Investor
DAG Ventures - Venture Investor
NanoDimension - Venture Investor
HBM BioCapital - Venture Investor
GV - Venture Investor
Celgene - Venture Investor
Industrial Investors - Venture Investor
Clough Capital Partners
